People: Theravance, Inc. (THRX.O)

THRX.O on Consolidated Issue listed on NASDAQ Global Market

10.21USD
9 Feb 2010
Price Change (% chg)

$0.36 (+3.65%)
Prev Close
$10.21
Open
--
Day's High
$10.31
Day's Low
$9.69
Volume
411,335
Avg. Vol
527,704
52-wk High
$18.56
52-wk Low
$9.65

view people for:

Summary

Name Age Since Current Position
Vagelos, P. Roy 79 1996 Chairman of the Board
Winningham, Rick 49 2001 Chief Executive Officer, Director
Aguiar, Michael 42 2005 Chief Financial Officer, Senior Vice President
Shafer, Bradford 48 1999 Senior Vice President, General Counsel, Secretary
Mammen, Mathai 41 2008 Senior Vice President - Research
Blum, Leonard 48 2007 Senior Vice President, Chief Commercial Officer
Drazan, Jeffrey 50 1999 Director
Gunderson, Robert 57 1999 Director
Levine, Arnold 69 2003 Director
Waltrip, William 71 2000 Director
Whitesides, George 69 1996 Director
Young, William 64 2001 Director
Malkiel, Burton 76 2007 Director
» Insider Trading

Biographies

Name Description
Vagelos, P. Roy Dr. P. Roy Vagelos, M.D., co-founded Theravance in 1996 and has served as Chairman of the Board of Directors of Theravance, Inc. since inception. Dr. Vagelos served as Chief Executive Officer of Merck & Co., Inc., from 1985 to 1994, and Chairman of the board of directors of Merck from 1986 until 1994. Dr. Vagelos is Chairman of the board of directors of Regeneron Pharmaceuticals, Inc. Dr. Vagelos holds an M.D. from Columbia University College of Physicians and Surgeons and an A.B. degree from the University of Pennsylvania.
Winningham, Rick Mr. Rick E Winningham joined Theravance, Inc. as Chief Executive Officer and member of the Board of Directors in October 2001. From 1997 to 2001 he served as President, Bristol-Myers Squibb Oncology/Immunology/ Oncology Therapeutics Network (OTN) and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN at Bristol-Myers Squibb, Mr. Winningham also had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, Oncology/ Metabolics and GU/GI/Neuroscience therapeutic areas. Mr. Winningham held various management positions with Bristol-Myers Squibb and its predecessor, Bristol-Myers, since 1986. Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. degree from Southern Illinois University.
Aguiar, Michael Mr. Michael W. Aguiar joined Theravance, Inc. as Senior Vice President and Chief Financial Officer in March 2005. Prior to joining Theravance, Mr. Aguiar served as Vice President of Finance at Gilead Sciences, Inc., a biopharmaceutical company, since 2002. Prior to Gilead Sciences, Inc., Mr. Aguiar served as Vice President of Finance at Immunex Corporation, a biopharmaceutical company, from 2001 to 2002. From 1995 to 2001, he was with Honeywell International in a variety of positions, including, most recently CFO and Vice President Finance for Honeywell Electronic Materials Strategic Business Unit. Mr. Aguiar earned a B.S. in Biology from UC Irvine and an M.B.A. in Finance from the University of Michigan.
Shafer, Bradford Mr. Bradford J. Shafer joined Theravance, Inc. as Senior Vice President, General Counsel and Secretary in August 1999. From 1996 to 1999 he served as General Counsel of Heartport, Inc., a cardiovascular medical device company. From 1993 to 1996 Mr. Shafer was a partner in the Business and Technology Group at the law firm of Brobeck, Phleger & Harrison LLP. Mr. Shafer holds a J.D. from the University of California, Hastings College of the Law, where he was Editor-in-Chief of The Hastings Constitutional Law Quarterly, and a B.A. from the University of the Pacific, where he graduated magna cum laude.
Mammen, Mathai Dr. Mathai Mammen, M.D., Ph.D., co-founded Theravance, Inc. in 1996. He was promoted to Senior Vice President, Research, in January 2008. He has served in various positions in both the Medicinal Chemistry Department and the Molecular and Cellular Biology Department, most recently as Vice President, Molecular and Cellular Biology, responsible for all molecular pharmacology, molecular biology, cell biology, microbiology and enzymology activities in support of projects in both Research and Development. Dr. Mammen obtained his M.D. from Harvard Medical School/Massachusetts Institute of Technology, and his Ph.D. in Physical Organic Chemistry from Harvard University. Dr. Mammen obtained his B.S. in Chemistry from Dalhousie University in Halifax, Nova Scotia.
Blum, Leonard Mr. Leonard M. Blum joined Theravance, Inc. as Senior Vice President and Chief Commercial Officer in July 2007. Prior to joining Theravance, Mr. Blum served as Senior Vice President of Sales and Marketing at ICOS Corporation. From 1987-2000, Mr. Blum held positions of increasing responsibility in marketing and sales management at Merck & Co. in both U.S. and international markets. Mr. Blum earned an M.B.A. from Stanford University, studied Finance as a Fulbright Fellow at the University of Zurich, and received an A.B. in Economics, magna cum laude, from Princeton University. Mr. Blum served as an officer in the U.S. Army Special Forces.
Drazan, Jeffrey Mr. Jeffrey M. Drazan is Director of Theravance, Inc. since December 1999. Mr. Drazan has been a General Partner with Sierra Ventures, a private venture capital firm, since 1984. Mr. Drazan has also been a Managing Director of Bertram Capital, a private equity firm, since September 2006. He also serves as a director of several private companies. Mr. Drazan holds an M.B.A. degree from New York University's Graduate School of Business Administration and a B.S.E. degree in Engineering from Princeton University.
Gunderson, Robert Mr. Robert V. Gunderson, Jr. is Director of Theravance, Inc. since September 1999. He is a founding partner of the law firm of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, where he has practiced since 1995. Mr. Gunderson currently serves as a director of a number of private companies. Mr. Gunderson holds a J.D. from the University of Chicago, where he was Executive Editor of The University of Chicago Law Review. Mr. Gunderson also received an M.B.A. in Finance from The Wharton School, University of Pennsylvania and an M.A. from Stanford University.
Levine, Arnold Dr. Arnold J. Levine, Ph.D., is Director of Theravance, Inc. from inception until February 2002. He rejoined the Board of Directors in June 2003. Dr. Levine is currently a professor at The Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine, New Brunswick, NJ, and a professor at the Institute for Advanced Study, Princeton, NJ, positions he has held since January 2003. He was President of The Rockefeller University from 1998 until his retirement in February 2002. He was the Harry C. Wiess Professor in Life Sciences and former Chairman of the Department of Molecular Biology at Princeton University from 1984 until 1996. Dr. Levine is a member of the board of directors of Life Technologies, Inc. and Infinity Pharmaceuticals, Inc. He is a member of the National Academy of Sciences. Dr. Levine was Editor-in-Chief of the Journal of Virology from 1984 to 1994 and is a member of scientific advisory boards of several cancer centers. Dr. Levine holds a Ph.D. in Microbiology from the University of Pennsylvania and a B.A. from Harpur College, State University of New York at Binghamton.
Waltrip, William Mr. William H. Waltrip is Director of Theravance since April 2000. Mr. Waltrip served from 1993 until 2003 as Chairman of the board of directors of Technology Solutions Company, a systems integration company, and from 1993 until 1995 he was Chief Executive Officer of that company. From 1995 to 1998 he also served as Chairman of Bausch & Lomb Inc., and during 1996 and 2002 was the company's Chief Executive Officer. From 1991 to 1993 he was Chairman and Chief Executive Officer of Biggers Brothers, Inc., a food service distribution company, and was a consultant to private industry from 1988 to 1991. From 1985 to 1988 he served as President and Chief Operating Officer of IU International Corporation, a transportation, environmental and distribution company. Earlier, he had been President, Chief Executive Officer and a director of Purolator Courier Corporation. He is a member of the board of directors of Charles River Laboratories Corporation and Thomas & Betts Corporation.
Whitesides, George Dr. George M. Whitesides, Ph.D., co-founded Theravance, Inc. in 1996 and has served as a member of the Board of Directors since inception. He has been Woodford L. and Ann A. Flowers University Professor at Harvard University since 2004. From 1986 until 2004, Dr. Whitesides was Mallinckrodt Professor of Chemistry at Harvard University. From 1982 until 1991 he was a member of the Department of Chemistry at Harvard University and Chairman of the Department of Chemistry from 1986 until 1989. He was a faculty member of the Massachusetts Institute of Technology from 1964 until 1982. Dr. Whitesides was a 1998 recipient of the National Medal of Science. He is a member of the editorial boards of 14 scientific journals. He is also a member of the board of directors of Surface Logix, Inc., Nano-Terra Inc., Arsenal Biomedical, Inc., Rohm and Haas Company, and Hughes Research Laboratories, L.L.C. Dr. Whitesides holds a Ph.D. in Chemistry from the California Institute of Technology and a B.A. from Harvard University.
Young, William Mr. William D. Young is Director of Theravance, Inc. since April 2001. Mr. Young has been Chairman of the board of directors and Chief Executive Officer of Monogram Biosciences, Inc. since 1999. From 1980 to 1999 Mr. Young was employed at Genentech, Inc., most recently as Chief Operating Officer. Prior to joining Genentech, Mr. Young worked at Eli Lilly and Company for 14 years and held various positions in production and process engineering, antibiotic process development and production management. He is a member of the board of directors of Biogen Idec, Inc. Mr. Young received his M.B.A. from Indiana University and his B.S. in Chemical Engineering from Purdue University, and an honorary Doctorate of Engineering from Purdue University. Mr. Young is a member of The National Academy of Engineering.
Malkiel, Burton Dr. Burton G. Malkiel, Ph.D., joined the Board of Directors of Theravance, Inc. in July 2007. Dr. Malkiel is the Chemical Bank Chairman's Professor of Economics at Princeton University. He is widely published in finance, the valuation of stocks and bonds and the operation of financial markets in the United States. He has also served as a member of the Council of Economic Advisors under the administration of U.S. President Gerald R. Ford and was Dean at the School of Management and the William S. Beinecke Professor of Management at Yale University. Dr. Malkiel served as an officer in the United States Army Finance Corps and as an investment banker at Smith, Barney & Co. before earning his doctoral degree. Dr. Malkiel is an investment committee member of the American Philosophical Society and the Corvina Foundation and serves on the boards of several companies including Vanguard Group Ltd and Genmab A/S. He is also the Chief Investment Officer of Alpha Shares. He received his B.A. degree in Economics from Harvard University, a M.B.A. from Harvard Graduate School of Business Administration and a Ph.D. in Economics and Finance from Princeton University.

Basic Compensation

Name Fiscal Year Total
Vagelos, P. Roy --
Winningham, Rick 2,127,400
Aguiar, Michael 1,393,200
Shafer, Bradford 732,339
Mammen, Mathai 1,155,080
Blum, Leonard 1,501,070
Drazan, Jeffrey --
Gunderson, Robert --
Levine, Arnold --
Waltrip, William --
Whitesides, George --
Young, William --
Malkiel, Burton --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Vagelos, P. Roy 0 0
Winningham, Rick 1,367,739 19,620,260
Aguiar, Michael 175,000 806,750
Shafer, Bradford 208,530 2,560,312
Mammen, Mathai 0 0
Blum, Leonard 0 0
Drazan, Jeffrey 0 0
Gunderson, Robert 0 0
Levine, Arnold 0 0
Waltrip, William 0 0
Whitesides, George 0 0
Young, William 0 0
Malkiel, Burton 0 0

Insider Trading

Name Shares Traded Price
VAGELOS P ROY 200,000 $8.53
BRINKLEY DAVID L 1,956 $13.01
SHAFER BRADFORD J 971 $14.04
MAMMEN MATHAI 1,100 $14.04
WINNINGHAM RICK E 2,364 $14.04
BRINKLEY DAVID L 704 $14.04
AGUIAR MICHAEL W 1,382 $14.04
BLUM LEONARD M 1,114 $14.04
BRINKLEY DAVID L 9,000 $8.53
BRINKLEY DAVID L 9,000 $17.86
AGUIAR MICHAEL W 4,468 $18.20
MAMMEN MATHAI 1,071 $15.65
WINNINGHAM RICK E 2,303 $15.65
BRINKLEY DAVID L 206 $15.65
BLUM LEONARD M 1,084 $15.65
AGUIAR MICHAEL W 1,347 $15.65
SHAFER BRADFORD J 946 $15.65
BLUM LEONARD M 1,086 $14.06
AGUIAR MICHAEL W 1,347 $14.06
WINNINGHAM RICK E 2,303 $14.06
SHAFER BRADFORD J 946 $14.06
MAMMEN MATHAI 1,071 $14.06
LEVINE ARNOLD J 6,000 $0.00
GUNDERSON ROBERT V JR 6,000 $0.00
YOUNG WILLIAM D 6,000 $0.00
» Full list on Insider Trading
view people for: